JP2014524461A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524461A5 JP2014524461A5 JP2014526537A JP2014526537A JP2014524461A5 JP 2014524461 A5 JP2014524461 A5 JP 2014524461A5 JP 2014526537 A JP2014526537 A JP 2014526537A JP 2014526537 A JP2014526537 A JP 2014526537A JP 2014524461 A5 JP2014524461 A5 JP 2014524461A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- hydroxypyridazin
- ethyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 50
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 125000002837 carbocyclic group Chemical group 0.000 claims 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- JTOTUBPVWVOXBU-UHFFFAOYSA-N 6-[2-[5-(trifluoromethyl)pyridin-3-yl]ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C=C(C=NC=2)C(F)(F)F)=N1 JTOTUBPVWVOXBU-UHFFFAOYSA-N 0.000 claims 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 102000004674 D-amino-acid oxidase Human genes 0.000 claims 2
- 108010003989 D-amino-acid oxidase Proteins 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229960004372 aripiprazole Drugs 0.000 claims 2
- 230000003796 beauty Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229960001848 lamotrigine Drugs 0.000 claims 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 229960001816 oxcarbazepine Drugs 0.000 claims 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 229960001534 risperidone Drugs 0.000 claims 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 229960000607 ziprasidone Drugs 0.000 claims 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 1
- ODAJAZMNOCKMGG-UHFFFAOYSA-N 4-[2-(5,6-dioxo-1,2-dihydropyridazin-3-yl)ethyl]benzonitrile Chemical compound N1C(=O)C(O)=CC(CCC=2C=CC(=CC=2)C#N)=N1 ODAJAZMNOCKMGG-UHFFFAOYSA-N 0.000 claims 1
- PMHDSACGRKBACK-UHFFFAOYSA-N 4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound S1C=CC2=C1C=C(C(=O)O)N2 PMHDSACGRKBACK-UHFFFAOYSA-N 0.000 claims 1
- RPGUWXSOVJOVCU-UHFFFAOYSA-N 6-(1-phenylcyclopropyl)-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(C2(CC2)C=2C=CC=CC=2)=N1 RPGUWXSOVJOVCU-UHFFFAOYSA-N 0.000 claims 1
- XOTMJYKZULIBIT-UHFFFAOYSA-N 6-(2-cyclohexylethyl)-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC2CCCCC2)=N1 XOTMJYKZULIBIT-UHFFFAOYSA-N 0.000 claims 1
- FROLIVDWLCPSEK-UHFFFAOYSA-N 6-(2-cyclopentylethyl)-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC2CCCC2)=N1 FROLIVDWLCPSEK-UHFFFAOYSA-N 0.000 claims 1
- JGLGHUJJSNRHMS-UHFFFAOYSA-N 6-(2-cyclopropylethyl)-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC2CC2)=N1 JGLGHUJJSNRHMS-UHFFFAOYSA-N 0.000 claims 1
- LQVOQKJUHJKVFE-UHFFFAOYSA-N 6-(2-phenylethyl)-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C=CC=CC=2)=N1 LQVOQKJUHJKVFE-UHFFFAOYSA-N 0.000 claims 1
- MGYRWLUCOHDAFI-UHFFFAOYSA-N 6-(cyclohexylmethyl)-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CC2CCCCC2)=N1 MGYRWLUCOHDAFI-UHFFFAOYSA-N 0.000 claims 1
- WEPLZOHZMRRBOD-UHFFFAOYSA-N 6-(cyclopropylmethyl)-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CC2CC2)=N1 WEPLZOHZMRRBOD-UHFFFAOYSA-N 0.000 claims 1
- DVQGQOMJOMJZDZ-UHFFFAOYSA-N 6-[(2-chloro-6-fluorophenyl)methyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CC=2C(=CC=CC=2F)Cl)=N1 DVQGQOMJOMJZDZ-UHFFFAOYSA-N 0.000 claims 1
- JAQHPNDRJKKANW-UHFFFAOYSA-N 6-[(2-chlorophenyl)methyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CC=2C(=CC=CC=2)Cl)=N1 JAQHPNDRJKKANW-UHFFFAOYSA-N 0.000 claims 1
- ZVHYXSBGOWCHME-UHFFFAOYSA-N 6-[(2-fluorophenyl)methyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CC=2C(=CC=CC=2)F)=N1 ZVHYXSBGOWCHME-UHFFFAOYSA-N 0.000 claims 1
- IBJIPOGULUXHDV-UHFFFAOYSA-N 6-[(3-chlorophenyl)methyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CC=2C=C(Cl)C=CC=2)=N1 IBJIPOGULUXHDV-UHFFFAOYSA-N 0.000 claims 1
- CUPIWKUHGMMZRU-UHFFFAOYSA-N 6-[(3-fluorophenyl)methyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CC=2C=C(F)C=CC=2)=N1 CUPIWKUHGMMZRU-UHFFFAOYSA-N 0.000 claims 1
- GLISJUJBXLSAGN-UHFFFAOYSA-N 6-[(3-methylphenyl)methyl]-1,2-dihydropyridazine-3,4-dione Chemical compound CC1=CC=CC(CC2=NNC(=O)C(O)=C2)=C1 GLISJUJBXLSAGN-UHFFFAOYSA-N 0.000 claims 1
- NTQJIGODKGILKS-UHFFFAOYSA-N 6-[(4-chlorophenyl)methyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CC=2C=CC(Cl)=CC=2)=N1 NTQJIGODKGILKS-UHFFFAOYSA-N 0.000 claims 1
- UXYOJAMXZPTQPE-UHFFFAOYSA-N 6-[(4-chlorophenyl)methylsulfanyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(SCC=2C=CC(Cl)=CC=2)=N1 UXYOJAMXZPTQPE-UHFFFAOYSA-N 0.000 claims 1
- YAVXFJCVIMSMCC-UHFFFAOYSA-N 6-[(4-fluorophenyl)methyl-methylamino]-1,2-dihydropyridazine-3,4-dione Chemical compound C1=C(O)C(=O)NN=C1N(C)CC1=CC=C(F)C=C1 YAVXFJCVIMSMCC-UHFFFAOYSA-N 0.000 claims 1
- OQWCQPBODXWWIY-UHFFFAOYSA-N 6-[(4-fluorophenyl)methyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CC=2C=CC(F)=CC=2)=N1 OQWCQPBODXWWIY-UHFFFAOYSA-N 0.000 claims 1
- NSNMVUVQLQLHEY-UHFFFAOYSA-N 6-[(4-methylphenyl)methyl]-1,2-dihydropyridazine-3,4-dione Chemical compound C1=CC(C)=CC=C1CC1=NNC(=O)C(O)=C1 NSNMVUVQLQLHEY-UHFFFAOYSA-N 0.000 claims 1
- MPLXLPDKXNWBGA-UHFFFAOYSA-N 6-[1-(4-fluorophenyl)cyclopropyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(C2(CC2)C=2C=CC(F)=CC=2)=N1 MPLXLPDKXNWBGA-UHFFFAOYSA-N 0.000 claims 1
- OUIUZIBDTPYHBB-UHFFFAOYSA-N 6-[1-(4-fluorophenyl)ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound C1=C(O)C(=O)NN=C1C(C)C1=CC=C(F)C=C1 OUIUZIBDTPYHBB-UHFFFAOYSA-N 0.000 claims 1
- KZLXXHVRWAPMOL-UHFFFAOYSA-N 6-[1-[3-(trifluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound C1=C(O)C(=O)NN=C1C(C)C1=CC=CC(C(F)(F)F)=C1 KZLXXHVRWAPMOL-UHFFFAOYSA-N 0.000 claims 1
- OITVJADMOJUVES-UHFFFAOYSA-N 6-[1-[4-(trifluoromethyl)phenyl]cyclopropyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(C2(CC2)C=2C=CC(=CC=2)C(F)(F)F)=N1 OITVJADMOJUVES-UHFFFAOYSA-N 0.000 claims 1
- OJTADJYTNWQVQR-UHFFFAOYSA-N 6-[2-(2,4-difluorophenyl)ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C(=CC(F)=CC=2)F)=N1 OJTADJYTNWQVQR-UHFFFAOYSA-N 0.000 claims 1
- BVKXSMYEDPXLIT-UHFFFAOYSA-N 6-[2-(2-chloro-6-fluorophenyl)ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C(=CC=CC=2F)Cl)=N1 BVKXSMYEDPXLIT-UHFFFAOYSA-N 0.000 claims 1
- MRTSKJFBZYCZPQ-UHFFFAOYSA-N 6-[2-(2-fluorophenyl)ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C(=CC=CC=2)F)=N1 MRTSKJFBZYCZPQ-UHFFFAOYSA-N 0.000 claims 1
- REIDEVKETREBHV-UHFFFAOYSA-N 6-[2-(3,4-difluorophenyl)ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C=C(F)C(F)=CC=2)=N1 REIDEVKETREBHV-UHFFFAOYSA-N 0.000 claims 1
- PUUZMWDYPCCOKE-UHFFFAOYSA-N 6-[2-(3,4-dimethoxyphenyl)ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound C1=C(OC)C(OC)=CC=C1CCC1=NNC(=O)C(O)=C1 PUUZMWDYPCCOKE-UHFFFAOYSA-N 0.000 claims 1
- BLEWCUQOJLGDAH-UHFFFAOYSA-N 6-[2-(3,5-difluorophenyl)ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C=C(F)C=C(F)C=2)=N1 BLEWCUQOJLGDAH-UHFFFAOYSA-N 0.000 claims 1
- DSQGKFJGCNPPRX-UHFFFAOYSA-N 6-[2-(3-chlorophenyl)ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C=C(Cl)C=CC=2)=N1 DSQGKFJGCNPPRX-UHFFFAOYSA-N 0.000 claims 1
- SGRRWLUYJCYTST-UHFFFAOYSA-N 6-[2-(3-fluorophenyl)ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C=C(F)C=CC=2)=N1 SGRRWLUYJCYTST-UHFFFAOYSA-N 0.000 claims 1
- VXMITFXRZIEUCJ-UHFFFAOYSA-N 6-[2-(4-fluorophenyl)ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C=CC(F)=CC=2)=N1 VXMITFXRZIEUCJ-UHFFFAOYSA-N 0.000 claims 1
- RGWRLRXVBWKUIQ-UHFFFAOYSA-N 6-[2-(4-methoxycyclohexyl)ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound C1CC(OC)CCC1CCC1=NNC(=O)C(O)=C1 RGWRLRXVBWKUIQ-UHFFFAOYSA-N 0.000 claims 1
- POONXLSXLZKJPU-UHFFFAOYSA-N 6-[2-(oxan-4-yl)ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC2CCOCC2)=N1 POONXLSXLZKJPU-UHFFFAOYSA-N 0.000 claims 1
- SLHOHUJHXJOCDY-UHFFFAOYSA-N 6-[2-[2,4-bis(trifluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C(=CC(=CC=2)C(F)(F)F)C(F)(F)F)=N1 SLHOHUJHXJOCDY-UHFFFAOYSA-N 0.000 claims 1
- NCQHKFSSNRZHOE-UHFFFAOYSA-N 6-[2-[2-chloro-4-(trifluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C(=CC(=CC=2)C(F)(F)F)Cl)=N1 NCQHKFSSNRZHOE-UHFFFAOYSA-N 0.000 claims 1
- UMQDGSCEGMTBAR-UHFFFAOYSA-N 6-[2-[2-methyl-4-(trifluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound CC1=CC(C(F)(F)F)=CC=C1CCC1=NNC(=O)C(O)=C1 UMQDGSCEGMTBAR-UHFFFAOYSA-N 0.000 claims 1
- CIYVWZNJISOLST-UHFFFAOYSA-N 6-[2-[3,4-bis(trifluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C=C(C(=CC=2)C(F)(F)F)C(F)(F)F)=N1 CIYVWZNJISOLST-UHFFFAOYSA-N 0.000 claims 1
- WNDBVELSJXWVGU-UHFFFAOYSA-N 6-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C=C(F)C(=C(F)C=2)C(F)(F)F)=N1 WNDBVELSJXWVGU-UHFFFAOYSA-N 0.000 claims 1
- WFTLWNWHERTNSX-UHFFFAOYSA-N 6-[2-[3-(difluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C=C(C=CC=2)C(F)F)=N1 WFTLWNWHERTNSX-UHFFFAOYSA-N 0.000 claims 1
- FIDAQQRAMNFEGF-UHFFFAOYSA-N 6-[2-[3-(trifluoromethoxy)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C=C(OC(F)(F)F)C=CC=2)=N1 FIDAQQRAMNFEGF-UHFFFAOYSA-N 0.000 claims 1
- ZYHBNBNPWBZULJ-UHFFFAOYSA-N 6-[2-[3-(trifluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C=C(C=CC=2)C(F)(F)F)=N1 ZYHBNBNPWBZULJ-UHFFFAOYSA-N 0.000 claims 1
- UTBDPMQSHUQFGC-UHFFFAOYSA-N 6-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-3,4-bis(phenylmethoxy)pyridazine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC=C1CCC(N=N1)=CC(OCC=2C=CC=CC=2)=C1OCC1=CC=CC=C1 UTBDPMQSHUQFGC-UHFFFAOYSA-N 0.000 claims 1
- LCYPNYGPBYWVPH-UHFFFAOYSA-N 6-[2-[3-fluoro-4-(trifluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C=C(F)C(=CC=2)C(F)(F)F)=N1 LCYPNYGPBYWVPH-UHFFFAOYSA-N 0.000 claims 1
- UNNCXQLEZFMIJP-UHFFFAOYSA-N 6-[2-[5-(trifluoromethyl)pyridin-2-yl]ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2N=CC(=CC=2)C(F)(F)F)=N1 UNNCXQLEZFMIJP-UHFFFAOYSA-N 0.000 claims 1
- XYAZCFMABJQHTG-UHFFFAOYSA-N 6-[2-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CCC=2C=NC(=CC=2)C(F)(F)F)=N1 XYAZCFMABJQHTG-UHFFFAOYSA-N 0.000 claims 1
- YMEUAOOCXBLSPK-UHFFFAOYSA-N 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=N1 YMEUAOOCXBLSPK-UHFFFAOYSA-N 0.000 claims 1
- FZVVPBGTVBQKSW-UHFFFAOYSA-N 6-[[3-(trifluoromethyl)phenyl]methyl]-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CC=2C=C(C=CC=2)C(F)(F)F)=N1 FZVVPBGTVBQKSW-UHFFFAOYSA-N 0.000 claims 1
- YHGODDQJKSTLBC-UHFFFAOYSA-N 6-[cyclohexylmethyl(methyl)amino]-1,2-dihydropyridazine-3,4-dione Chemical compound C1=C(O)C(=O)NN=C1N(C)CC1CCCCC1 YHGODDQJKSTLBC-UHFFFAOYSA-N 0.000 claims 1
- VBRWTUPXJUSBQW-UHFFFAOYSA-N 6-[cyclopropylmethyl(methyl)amino]-1,2-dihydropyridazine-3,4-dione Chemical compound C1=C(O)C(=O)NN=C1N(C)CC1CC1 VBRWTUPXJUSBQW-UHFFFAOYSA-N 0.000 claims 1
- YYOVQEHTCUDCHA-UHFFFAOYSA-N 6-benzyl-1,2-dihydropyridazine-3,4-dione Chemical compound N1C(=O)C(O)=CC(CC=2C=CC=CC=2)=N1 YYOVQEHTCUDCHA-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- BGCDTMGUYBEEAM-UHFFFAOYSA-N CC=1C=C(CCN2N=CC=CC2=O)C=CC=1C(F)(F)F Chemical compound CC=1C=C(CCN2N=CC=CC2=O)C=CC=1C(F)(F)F BGCDTMGUYBEEAM-UHFFFAOYSA-N 0.000 claims 1
- 229940121734 D-amino-acid oxidase inhibitor Drugs 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- 208000020186 Schizophreniform disease Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 239000012320 chlorinating reagent Substances 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- -1 imidazo [1,2-a] pyridinyl Chemical group 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229960001722 verapamil Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1114399.7 | 2011-08-22 | ||
| GBGB1114399.7A GB201114399D0 (en) | 2011-08-22 | 2011-08-22 | Novel compounds |
| GB201118658A GB201118658D0 (en) | 2011-10-27 | 2011-10-27 | Novel compounds |
| GB1118658.2 | 2011-10-27 | ||
| GBGB1203533.3A GB201203533D0 (en) | 2012-02-29 | 2012-02-29 | Novel compounds |
| GB1203533.3 | 2012-02-29 | ||
| PCT/GB2012/000672 WO2013027000A1 (en) | 2011-08-22 | 2012-08-21 | Pyridazinone compounds and their use as daao inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014524461A JP2014524461A (ja) | 2014-09-22 |
| JP2014524461A5 true JP2014524461A5 (enExample) | 2016-01-14 |
| JP6022573B2 JP6022573B2 (ja) | 2016-11-09 |
Family
ID=46758786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014526537A Active JP6022573B2 (ja) | 2011-08-22 | 2012-08-21 | ピリダジノン化合物、及びｄａａｏ阻害剤としてのその使用 |
Country Status (38)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| US9238716B2 (en) | 2011-03-28 | 2016-01-19 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| MX363734B (es) | 2011-10-27 | 2019-03-29 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco. |
| UA111861C2 (uk) | 2011-11-15 | 2016-06-24 | Такеда Фармасьютікал Компані Лімітед | Ароматична гетероциклічна сполука дигідрокси |
| WO2014025993A1 (en) | 2012-08-08 | 2014-02-13 | The Johns Hopkins University | Inhibitors of d-amino acid oxidase |
| GB201222711D0 (en) * | 2012-12-17 | 2013-01-30 | Takeda Pharmaceutical | Novel compounds |
| US9956113B2 (en) | 2013-03-12 | 2018-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method and system for regulating core body temperature |
| GB201403944D0 (en) * | 2014-03-06 | 2014-04-23 | Takeda Pharmaceutical | New use |
| KR20160147868A (ko) * | 2014-04-30 | 2016-12-23 | 위펑 제인 쳉 | D-아미노산 옥시다제 억제제로서 공지된 화합물의 용도 |
| CA2990172A1 (en) | 2015-06-19 | 2016-12-22 | Massachusetts Institute Of Technology | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
| WO2019043635A1 (en) | 2017-09-01 | 2019-03-07 | Richter Gedeon Nyrt. | COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE |
| US10336724B2 (en) * | 2017-10-18 | 2019-07-02 | Syneurx International (Taiwan) Corp. | D-amino acid oxidase inhibitors and therapeutic uses thereof |
| US12403034B2 (en) | 2019-01-31 | 2025-09-02 | Flotherm, Inc. | Sleeve-based body temperature regulation |
| CN109725092A (zh) * | 2019-03-19 | 2019-05-07 | 北京和合医学诊断技术股份有限公司 | 检测血液中齐拉西酮含量的液相色谱分析方法 |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
| JP2024508860A (ja) | 2021-03-01 | 2024-02-28 | 武田薬品工業株式会社 | 認知機能障害の処置のためのルバダキシスタットの使用 |
| US12502308B2 (en) | 2021-07-01 | 2025-12-23 | Flotherm, Inc. | Flexible heating pads |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU75958A1 (enExample) | 1976-10-08 | 1978-05-16 | ||
| CH636632A5 (de) | 1976-10-08 | 1983-06-15 | Ciba Geigy Ag | Neues verfahren zur herstellung von schwermetallkomplexen. |
| GB2025416A (en) | 1978-07-14 | 1980-01-23 | Pfizer Ltd | Mercaptopyridazinethione antifungal agents |
| GB8421427D0 (en) | 1984-08-23 | 1984-09-26 | Smith Kline French Lab | Chemical compounds |
| US4743685A (en) | 1985-09-26 | 1988-05-10 | E. R. Squibb & Sons, Inc. | 2-oxo-1-[[(substituted sulfonyl)amino]carbonyl]azetidines |
| EG18314A (en) | 1985-09-26 | 1993-02-28 | Squibb & Sons Inc | Process for preparing of 2-oxo-1((substituted sulfonyl)amino)carbonyl)-azitidines |
| DK170088A (da) | 1987-04-10 | 1988-10-11 | Hoffmann La Roche | Acylderivater |
| WO1989000423A1 (en) | 1987-07-09 | 1989-01-26 | Pfizer Inc. | 2-amino-5-hydroxy-4-pyrimidones |
| JPH01202875A (ja) | 1988-02-09 | 1989-08-15 | Fujitsu Ltd | 超伝導材料構造の製造方法 |
| US5244890A (en) | 1988-06-06 | 1993-09-14 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
| CA2020654A1 (en) | 1989-07-07 | 1991-01-08 | Yohko Akiyama | Stabilized fgf composition and production thereof |
| ATE128006T1 (de) | 1990-11-22 | 1995-10-15 | Cerestar Holding Bv | Verfahren zur herstellung von schokolade. |
| EP0544166A3 (en) | 1991-11-26 | 1993-11-03 | Hoffmann La Roche | Cephalosporinderivatives |
| GB9219313D0 (en) | 1992-09-11 | 1992-10-28 | Kodak Ltd | Method of forming a photographic colour image |
| JPH09504010A (ja) | 1993-10-20 | 1997-04-22 | ジ・アップジョン・カンパニー | 抗関節炎剤および抗炎症剤としてのピリミジノン |
| JP3708962B2 (ja) | 1994-08-24 | 2005-10-19 | アストラゼネカ・アクチエボラーグ | 治療に有用なスピロ−アザ二環式化合物 |
| JPH092534A (ja) | 1995-06-16 | 1997-01-07 | Terada Seisakusho:Kk | 茶貯蔵容器 |
| JPH0925234A (ja) | 1995-07-12 | 1997-01-28 | Wakunaga Pharmaceut Co Ltd | 脳疾患改善剤 |
| SE9504661D0 (sv) | 1995-12-22 | 1995-12-22 | Astra Pharma Inc | New compounds |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| AR013184A1 (es) | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| SE9702799D0 (sv) | 1997-07-25 | 1997-07-25 | Astra Ab | New compounds |
| US6525053B1 (en) | 1997-08-22 | 2003-02-25 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| WO1999010331A1 (en) | 1997-08-22 | 1999-03-04 | Abbott Laboratories | Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| ES2262322T3 (es) | 1998-06-10 | 2006-11-16 | Meiji Seika Kaisha, Ltd. | Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar. |
| ATE302759T1 (de) | 1998-10-27 | 2005-09-15 | Abbott Lab | Prostaglandin endoperoxyde h synthase biosynthese inhibitoren |
| SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| SE9903760D0 (sv) | 1999-10-18 | 1999-10-18 | Astra Ab | New compounds |
| SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
| SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| JP2002028187A (ja) | 2000-07-14 | 2002-01-29 | Toto Ltd | 車いす |
| SE0002729D0 (sv) | 2000-07-20 | 2000-07-20 | Astrazeneca Ab | Novel compound form |
| AU2001288432A1 (en) | 2000-09-01 | 2002-03-22 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| CN101486683B (zh) * | 2000-09-18 | 2011-12-21 | 卫材R&D管理有限公司 | 哒嗪酮和三嗪酮化合物及其作为药物制剂的用途 |
| DE60139506D1 (de) | 2000-12-28 | 2009-09-17 | Shionogi & Co | 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor |
| WO2002094794A1 (en) | 2001-05-18 | 2002-11-28 | Astrazeneca Ab | 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders |
| ES2280538T3 (es) | 2001-06-01 | 2007-09-16 | Astrazeneca Ab | Nuevo ligando para receptores nicotinicos de acetilcolina utiles en terapia. |
| AU2002339696A1 (en) | 2001-12-03 | 2003-06-17 | Genset S.A. | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors |
| ES2610611T3 (es) | 2002-01-18 | 2017-04-28 | Astellas Pharma Inc. | Derivado de 2-acilaminotiazol o sal del mismo |
| BR0309342A (pt) | 2002-04-18 | 2005-02-15 | Astrazeneca Ab | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas |
| DE60334536D1 (de) | 2002-04-18 | 2010-11-25 | Astrazeneca Ab | Furylverbindungen |
| MXPA04010190A (es) | 2002-04-18 | 2005-02-03 | Astrazeneca Ab | Compuestos heterociclicos. |
| WO2004000820A2 (en) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| SE0202465D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New compounds |
| SE0202430D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| SE0202598D0 (sv) | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
| BRPI0409649A (pt) | 2003-04-23 | 2006-04-25 | Pharmacia & Upjohn Co Llc | pirimidinonas e pirimidinotionas substituìdas como antagonistas de crf |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| CN1905873A (zh) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| MY141255A (en) | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
| RU2361862C2 (ru) | 2003-12-29 | 2009-07-20 | Сепракор Инк. | Пиррольные и пиразольные ингибиторы daao |
| DE602005017129D1 (de) | 2004-03-22 | 2009-11-26 | Lilly Co Eli | Pyridyl-derivate und ihre verwendung als mglu5-rezeptorantagonisten |
| WO2006135828A2 (en) | 2005-06-10 | 2006-12-21 | Memory Pharmaceuticals Corporation | Trisubstituted amines as phosphodiesterase 4 inhibitors |
| TWI375669B (en) | 2006-03-17 | 2012-11-01 | Sumitomo Chemical Co | Pyridazinone compound and use thereof |
| JP2009542683A (ja) * | 2006-06-30 | 2009-12-03 | セプラコア インコーポレーテッド | Ｄ−アミノ酸オキシダーゼの縮合ヘテロ環式阻害剤 |
| US7579370B2 (en) | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
| EP2074092A2 (en) | 2007-01-18 | 2009-07-01 | Sepracor Inc. | Inhibitors of d-amino acid oxidase |
| AR064962A1 (es) | 2007-01-22 | 2009-05-06 | Syngenta Participations Ag | Derivados de piridazina utiles como fungicidas |
| CN101730692A (zh) * | 2007-03-15 | 2010-06-09 | 先灵公司 | 用作葡聚糖合成酶抑制剂的哒嗪酮衍生物 |
| WO2008116301A1 (en) | 2007-03-28 | 2008-10-02 | Apotex Technologies Inc. | Fluorinated derivatives of deferiprone |
| WO2008156607A1 (en) * | 2007-06-12 | 2008-12-24 | Neurogen Corporation | Substituted pyrimidinones |
| JP2009002534A (ja) | 2007-06-19 | 2009-01-08 | Denso Corp | 熱交換器 |
| EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| WO2010017418A1 (en) | 2008-08-07 | 2010-02-11 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| WO2010058314A1 (en) * | 2008-11-18 | 2010-05-27 | Pfizer Inc. | Hydroxyquinolin-2(1h)-ones and derivatives thereof |
| EP2393360B1 (en) | 2009-02-05 | 2015-11-04 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds |
| US20130065857A1 (en) | 2009-10-12 | 2013-03-14 | Baylor College Of Medicine | Novel dxr inhibitors for antimicrobial therapy |
| KR20130044381A (ko) | 2010-03-04 | 2013-05-02 | 머크 샤프 앤드 돔 코포레이션 | 카테콜 ｏ－메틸 트랜스퍼라제의 억제제 및 정신병적 장애의 치료에서의 그의 용도 |
| JP5995728B2 (ja) | 2010-03-04 | 2016-09-21 | メルク・シャープ・エンド・ドーム・コーポレイション | カテコールｏ−メチルトランスフェラーゼの阻害剤および精神障害の治療におけるその使用 |
| PT2542084T (pt) | 2010-03-04 | 2018-03-23 | Merck Sharp & Dohme | Inibidores de catecol o-metil transferase e sua utilização no tratamento de distúrbios psicóticos |
| US20120046232A1 (en) | 2010-06-22 | 2012-02-23 | Medical University Of South Carolina | Compositions and methods for reducing relapse of addictive behavior |
| EP2723737A1 (en) | 2011-06-27 | 2014-04-30 | Kyorin Pharmaceutical Co., Ltd. | Bridged bicyclic compounds for the treatment of bacterial infections |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| JP2013051513A (ja) | 2011-08-30 | 2013-03-14 | Minebea Co Ltd | ダンパー及びそれを用いたスピーカ |
| UA111861C2 (uk) | 2011-11-15 | 2016-06-24 | Такеда Фармасьютікал Компані Лімітед | Ароматична гетероциклічна сполука дигідрокси |
| US8868710B2 (en) | 2011-11-18 | 2014-10-21 | Amazon Technologies, Inc. | Virtual network interface objects |
| GB201222711D0 (en) | 2012-12-17 | 2013-01-30 | Takeda Pharmaceutical | Novel compounds |
| EA201591540A1 (ru) | 2013-02-21 | 2016-01-29 | Такеда Фармасьютикал Компани Лимитед | Способ получения производных пиридазинона |
| GB201403944D0 (en) | 2014-03-06 | 2014-04-23 | Takeda Pharmaceutical | New use |
| JP5897196B1 (ja) | 2015-10-05 | 2016-03-30 | 大同化成工業株式会社 | 糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法 |
| EP3354283B1 (en) | 2017-06-20 | 2019-08-07 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical capsule composition comprising silodosin |
| US10336724B2 (en) | 2017-10-18 | 2019-07-02 | Syneurx International (Taiwan) Corp. | D-amino acid oxidase inhibitors and therapeutic uses thereof |
| PE20221341A1 (es) | 2019-09-16 | 2022-09-13 | Takeda Pharmaceuticals Co | Derivados de piridazin-3(2h)-ona fusionados con azol |
| JP2024508860A (ja) | 2021-03-01 | 2024-02-28 | 武田薬品工業株式会社 | 認知機能障害の処置のためのルバダキシスタットの使用 |
-
2012
- 2012-08-15 JO JOP/2012/0232A patent/JO3115B1/ar active
- 2012-08-21 PE PE2014000238A patent/PE20141208A1/es active IP Right Grant
- 2012-08-21 HU HUE12753164A patent/HUE026691T2/hu unknown
- 2012-08-21 PL PL12753164T patent/PL2748149T3/pl unknown
- 2012-08-21 JP JP2014526537A patent/JP6022573B2/ja active Active
- 2012-08-21 ME MEP-2016-2A patent/ME02319B/me unknown
- 2012-08-21 EP EP12753164.8A patent/EP2748149B9/en active Active
- 2012-08-21 AR ARP120103061A patent/AR087607A1/es active IP Right Grant
- 2012-08-21 PH PH1/2014/500405A patent/PH12014500405A1/en unknown
- 2012-08-21 HR HRP20151310TT patent/HRP20151310T2/hr unknown
- 2012-08-21 UY UY0001034280A patent/UY34280A/es not_active Application Discontinuation
- 2012-08-21 KR KR1020147007280A patent/KR101961851B1/ko not_active Expired - Fee Related
- 2012-08-21 GE GEAP201213407A patent/GEP20156372B/en unknown
- 2012-08-21 CN CN201280040586.3A patent/CN103748079B/zh active Active
- 2012-08-21 AU AU2012298335A patent/AU2012298335B2/en not_active Ceased
- 2012-08-21 PT PT127531648T patent/PT2748149E/pt unknown
- 2012-08-21 WO PCT/GB2012/000672 patent/WO2013027000A1/en not_active Ceased
- 2012-08-21 US US14/240,045 patent/US9290456B2/en active Active
- 2012-08-21 SI SI201230375T patent/SI2748149T1/sl unknown
- 2012-08-21 ES ES12753164.8T patent/ES2559631T3/es active Active
- 2012-08-21 AP AP2014007512A patent/AP2014007512A0/xx unknown
- 2012-08-21 MX MX2014000783A patent/MX2014000783A/es active IP Right Grant
- 2012-08-21 BR BR112014003906-2A patent/BR112014003906B1/pt active IP Right Grant
- 2012-08-21 DK DK12753164.8T patent/DK2748149T5/en active
- 2012-08-21 RS RS20160010A patent/RS54515B9/sr unknown
- 2012-08-21 MY MYPI2013004633A patent/MY180618A/en unknown
- 2012-08-21 EA EA201490471A patent/EA024956B1/ru unknown
- 2012-08-21 TW TW101130241A patent/TWI546289B/zh active
- 2012-08-21 CA CA2846204A patent/CA2846204C/en active Active
- 2012-08-22 US US13/591,859 patent/US20130052281A1/en not_active Abandoned
-
2013
- 2013-12-24 IL IL230143A patent/IL230143A/en active IP Right Grant
-
2014
- 2014-01-08 ZA ZA2014/00153A patent/ZA201400153B/en unknown
- 2014-02-17 EC ECSP14013215 patent/ECSP14013215A/es unknown
- 2014-02-17 CL CL2014000395A patent/CL2014000395A1/es unknown
- 2014-02-19 DO DO2014000036A patent/DOP2014000036A/es unknown
- 2014-03-18 CO CO14058009A patent/CO6910197A2/es unknown
- 2014-03-21 CR CR20140133A patent/CR20140133A/es unknown
-
2016
- 2016-01-07 CY CY20161100005T patent/CY1117105T1/el unknown
- 2016-01-21 SM SM201600023T patent/SMT201600023B/it unknown
- 2016-02-03 US US15/014,336 patent/US9931340B2/en active Active
-
2018
- 2018-02-20 US US15/899,561 patent/US10463663B2/en active Active
-
2019
- 2019-09-24 US US16/580,095 patent/US11129828B2/en not_active Expired - Fee Related
-
2021
- 2021-08-30 US US17/461,757 patent/US12186313B2/en active Active
-
2022
- 2022-10-06 AR ARP220102738A patent/AR127309A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524461A5 (enExample) | ||
| HRP20151310T2 (hr) | Spojevi piridazinona i njihova uporaba kao inhibitori daao | |
| RU2586974C2 (ru) | Ингибиторы катехол-о-метилтрансферазы и их применение при лечении психотических расстройств | |
| US8815926B2 (en) | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases | |
| JP4579346B2 (ja) | アミノ複素環式化合物 | |
| EP2549875B1 (en) | Soluble guanylate cyclase activators | |
| US8685993B2 (en) | Bi-heteroaryl compounds as Vps34 inhibitors | |
| EA018268B1 (ru) | Аналоги пиридона и пиридазона как модуляторы gpr119 | |
| US9815832B2 (en) | Azabenzimidazole compounds | |
| JP6258937B2 (ja) | 新規二環式ピリジン誘導体 | |
| JP2013519724A5 (enExample) | ||
| AU2004220382B2 (en) | Imidazol-4-yl-ethynyl-pyridine derivatives | |
| RU2507204C2 (ru) | Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона | |
| TWI629276B (zh) | 咪唑并嗒化合物 | |
| JP2008513514A5 (enExample) | ||
| RU2008141509A (ru) | Mglur5 модуляторы 1 | |
| IL258577A (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| JP2019530695A5 (enExample) | ||
| RU2014139601A (ru) | Ингибиторы серин/треониновых киназ | |
| CA2961489A1 (en) | Sgc stimulators | |
| RU2350616C2 (ru) | Производные пиразоло- и имидазопиримидина | |
| JP2019112433A (ja) | ４−アザインドール誘導体 | |
| JP2017502049A5 (enExample) | ||
| JP2018530591A5 (enExample) | ||
| RU2015100942A (ru) | Производное пиперидинилпиразолпиридина |